The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
Margaret Gatti-Mays, MD MPH, The Ohio State University, Columbus, OH, shares findings from a Phase I trial (NCT04248569) of a therapeutic vaccine targeting the DNAJ-PKAc chimera with nivolumab and ipilimumab for advanced fibrolamellar hepatocellular carcinoma (FLC). The study demonstrated acceptable safety and immunogenicity, and clinical benefit was observed in a substantial proportion of evaluable patients, with evidence suggesting a link between T cell reactivity and disease control. T cell exhaustion emerged as a mechanism of resistance in some cases. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
